By Jason Derry --
Gene Logic Inc. announced today will collaborate with Abbott Laboratories to discover drug candidates that can be returned to clinical development. Gene Logic analyzes drug candidates that were once involved in clinical trials, but then were discontinued for reasons not related to safety. Abbott hopes that Gene Logic can identify new therapeutic uses for the clinically safe drugs. Gene Logic will receive milestone payments for any candidate drug that Abbott decides to get back into clinical development and royalties on those that reach market. Gene Logic also has the option to exclusively license any drug candidate Abbott disregards. Gene Logic also has collaborative agreements with Pfizer and Roche.
Comments